Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection.

Cabral-Miranda G, Lim SM, Mohsen MO, Pobelov IV, Roesti ES, Heath MD, Skinner MA, Kramer MF, Martina BEE, Bachmann MF.

Vaccines (Basel). 2019 Jul 23;7(3). pii: E72. doi: 10.3390/vaccines7030072.

2.

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine.

Mohsen MO, Vogel M, Riether C, Muller J, Salatino S, Ternette N, Gomes AC, Cabral-Miranda G, El-Turabi A, Ruedl C, Kundig TM, Dermime S, Knuth A, Speiser DE, Bachmann MF.

Front Immunol. 2019 May 15;10:1015. doi: 10.3389/fimmu.2019.01015. eCollection 2019.

3.

Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, Stein JV, Riether C, Roesti E, Zha L, Engeroff P, El-Turabi A, Kundig TM, Vogel M, Skinner MA, Speiser DE, Knuth A, Kramer MF, Bachmann MF.

J Immunother Cancer. 2019 May 23;7(1):137. doi: 10.1186/s40425-019-0616-y.

4.

Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, Stein JV, Riether C, Roesti E, Zha L, Engeroff P, El-Turabi A, Kundig TM, Vogel M, Skinner MA, Speiser DE, Knuth A, Kramer MF, Bachmann MF.

J Immunother Cancer. 2019 Apr 26;7(1):114. doi: 10.1186/s40425-019-0587-z. Erratum in: J Immunother Cancer. 2019 May 23;7(1):137.

5.

Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases.

Klimek L, Kündig T, Kramer MF, Guethoff S, Jensen-Jarolim E, Schmidt-Weber CB, Palomares O, Mohsen MO, Jakob T, Bachmann M.

Allergo J Int. 2018;27(8):245-255. doi: 10.1007/s40629-018-0074-y. Epub 2018 Jul 9. Review.

6.

DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines.

Cabral-Miranda G, M Salman A, O Mohsen M, L Storni F, S Roesti E, A Skinner M, D Heath M, F Kramer M, M Khan S, J Janse C, V S Hill A, F Bachmann M.

Diseases. 2018 Nov 21;6(4). pii: E107. doi: 10.3390/diseases6040107.

7.

Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System.

Mohsen MO, Gomes AC, Vogel M, Bachmann MF.

Vaccines (Basel). 2018 Jul 2;6(3). pii: E37. doi: 10.3390/vaccines6030037. Review.

8.

An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcγRIIb.

Zha L, Leoratti FMS, He L, Mohsen MO, Cragg M, Storni F, Vogel M, Bachmann MF.

J Allergy Clin Immunol. 2018 Nov;142(5):1529-1536.e6. doi: 10.1016/j.jaci.2017.09.054. Epub 2018 Jan 31.

PMID:
29391255
9.

Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.

Cabral-Miranda G, Heath MD, Gomes AC, Mohsen MO, Montoya-Diaz E, Salman AM, Atcheson E, Skinner MA, Kramer MF, Reyes-Sandoval A, Bachmann MF.

Vaccines (Basel). 2017 Sep 27;5(4). pii: E32. doi: 10.3390/vaccines5040032.

10.

Major findings and recent advances in virus-like particle (VLP)-based vaccines.

Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF.

Semin Immunol. 2017 Dec;34:123-132. doi: 10.1016/j.smim.2017.08.014. Epub 2017 Sep 5. Review.

PMID:
28887001
11.

Therapeutic silence of pleiotrophin by targeted delivery of siRNA and its effect on the inhibition of tumor growth and metastasis.

Zha L, He L, Xie W, Cheng J, Li T, Mohsen MO, Lei F, Storni F, Bachmann M, Chen H, Zhang Y.

PLoS One. 2017 May 31;12(5):e0177964. doi: 10.1371/journal.pone.0177964. eCollection 2017.

12.

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.

Cabral-Miranda G, Heath MD, Mohsen MO, Gomes AC, Engeroff P, Flaxman A, Leoratti FMS, El-Turabi A, Reyes-Sandoval A, Skinner MA, Kramer MF, Bachmann MF.

Vaccines (Basel). 2017 May 2;5(2). pii: E10. doi: 10.3390/vaccines5020010.

13.

Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.

Mohsen MO, Gomes AC, Cabral-Miranda G, Krueger CC, Leoratti FM, Stein JV, Bachmann MF.

J Control Release. 2017 Apr 10;251:92-100. doi: 10.1016/j.jconrel.2017.02.031. Epub 2017 Feb 28.

PMID:
28257987

Supplemental Content

Loading ...
Support Center